Subthreshold nitric oxide synthase inhibition improves synergistic effects of subthreshold MMP-2/MLCK-mediated cardiomyocyte protection from hypoxic injury

J Cell Mol Med. 2016 Jun;20(6):1086-94. doi: 10.1111/jcmm.12827. Epub 2016 Mar 17.

Abstract

Injury of myocardium during ischaemia/reperfusion (I/R) is a complex and multifactorial process involving uncontrolled protein phosphorylation, nitration/nitrosylation by increased production of nitric oxide and accelerated contractile protein degradation by matrix metalloproteinase-2 (MMP-2). It has been shown that simultaneous inhibition of MMP-2 with doxycycline (Doxy) and myosin light chain kinase (MLCK) with ML-7 at subthreshold concentrations protects the heart from contractile dysfunction triggered by I/R in a synergistic manner. In this study, we showed that additional co-administration of nitric oxide synthase (NOS) inhibitor (1400W or L-NAME) in subthreshold concentrations improves this synergistic protection in the model of hypoxia-reoxygenation (H-R)-induced contractile dysfunction of cardiomyocytes. Isolated cardiomyocytes were subjected to 3 min. of hypoxia and 20 min. of reoxygenation in the presence or absence of the inhibitor cocktails. Contractility of cardiomyocytes was expressed as myocyte peak shortening. Inhibition of MMP-2 by Doxy (25-100 μM), MLCK by ML-7 (0.5-5 μM) and NOS by L-NAME (25-100 μM) or 1400W (25-100 μM) protected myocyte contractility after H-R in a concentration-dependent manner. Inhibition of these activities resulted in full recovery of cardiomyocyte contractility after H-R at the level of highest single-drug concentration. The combination of subthreshold concentrations of NOS, MMP-2 and MLCK inhibitors fully protected cardiomyocyte contractility and MLC1 from degradation by MMP-2. The observed protection with addition of L-NAME or 1400W was better than previously reported combination of ML-7 and Doxy. The results of this study suggest that addition of NOS inhibitor to the mixture of inhibitors is better strategy for protecting cardiomyocyte contractility.

Keywords: cardiomyocytes; contractile proteins; hypoxia-reoxygenation; matrix metalloproteinase-2; nitric oxide; phosphorylation; synergism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Azepines
  • Cardiotonic Agents / pharmacology*
  • Cell Hypoxia / drug effects
  • Doxycycline / pharmacology
  • Drug Synergism
  • Enzyme Inhibitors / pharmacology*
  • Imines / pharmacology
  • Immunoblotting
  • Male
  • Matrix Metalloproteinase 2 / metabolism*
  • Myocardial Contraction / drug effects
  • Myocytes, Cardiac / enzymology*
  • Myocytes, Cardiac / pathology*
  • Myosin-Light-Chain Kinase / metabolism*
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Naphthalenes
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase / antagonists & inhibitors*
  • Nitric Oxide Synthase / metabolism
  • Oxygen
  • Rats, Sprague-Dawley

Substances

  • Azepines
  • Cardiotonic Agents
  • Enzyme Inhibitors
  • Imines
  • N-((3-(aminomethyl)phenyl)methyl)ethanimidamide
  • Naphthalenes
  • ML 7
  • Nitric Oxide
  • Nitric Oxide Synthase
  • Myosin-Light-Chain Kinase
  • Matrix Metalloproteinase 2
  • Doxycycline
  • Oxygen
  • NG-Nitroarginine Methyl Ester

Grants and funding